Abstract
Irisin, a newly discovered myokine, plays an important role in maintaining energy balance and improving metabolic diseases. Tangeretin (TAN) is a natural active substance mainly found in the peel of citrus fruits, which has been reported to affect skeletal muscle function and prevent obesity-related metabolic diseases. However, the potential impact of TAN on the control of FNDC5/irisin expression remains poorly understood. This study utilized C2C12 cells, normal mice, and HFD-induced obese mouse models. Following treatment with TAN, metabolic activity was evaluated via metabolic cages, GTT, and ITT. The expression of FNDC5 in vivo and in vitro was examined by Q-PCR, Western blotting, and immunostaining, while the binding effect of TAN and SESN2 was analyzed by molecular dynamics. We found that TAN treatment promoted irisin production and secretion in both C2C12 myotubular cells and C57BL/6J mice. This rise in irisin levels was associated with the upregulation of FNDC5 expression, mediated via the SESN2/AMPK/PGC-1α signaling pathway. Furthermore, TAN supplementation effectively resisted the decrease in circulating irisin levels and activated the SESN2 signaling axis in skeletal muscle of HFD-fed mice, significantly improving metabolic parameters. These findings reveal that TAN counteracts HFD-induced decreases in irisin secretion and improves glucose and lipid metabolism by activating the SESN2/AMPK/PGC1-α/FNDC5 signaling axis.
Introduction
Skeletal muscle is a secretory organ that releases "myokines" to regulate energy balance. Irisin, cleaved from the FNDC5 protein, is typically released during exercise and helps drive fat-burning and metabolic health. Obesity and high-fat diets (HFD) suppress FNDC5/irisin expression, leading to metabolic dysfunction and insulin resistance. Researchers are seeking natural "exercise mimetics"—compounds that trigger these metabolic pathways. Tangeretin (TAN), a citrus flavonoid, has known anti-obesity effects, but its role in rescuing FNDC5/irisin levels was previously unclear.
Methods
The study employed in vitro, in vivo, and computational approaches. C2C12 mouse myotubes were treated with TAN to observe FNDC5 and irisin expression. Normal C57BL/6J mice and HFD-induced obese mice were given oral TAN (50 or 100 mg/kg) for eight weeks. Physiological profiling included metabolic cages for oxygen consumption (VO2) and energy expenditure (EE), MRI for body composition, and glucose/insulin tolerance tests (GTT/ITT). Molecular mechanisms were explored via molecular docking and 100-ns Molecular Dynamics (MD) simulations to model TAN binding to SESN2, using structural data from the Protein Data Bank (PDB ID: 5t0n).
Results
Cellular Effects of Tangeretin
In vitro experiments using C2C12 muscle cells demonstrated that TAN significantly increased FNDC5 mRNA and protein levels in a dose-dependent manner. This suggests that TAN directly stimulates the expression of the irisin precursor within muscle tissue.
Furthermore, TAN treatment led to a significant increase in secreted irisin levels in the cell culture medium, confirming that the increased FNDC5 expression translates into higher levels of the active myokine.
Metabolic Rescue in Obese Mice
In HFD-fed mice, TAN supplementation reduced body weight gain and fat mass while improving glucose and insulin tolerance. Metabolic cage data showed higher VO2 and EE in TAN-treated HFD mice. A lower respiratory exchange ratio (RER) was observed, indicating a metabolic shift toward fat oxidation. MD simulations confirmed that TAN binds stably to the SESN2 protein pocket with a binding free energy of -36.58 ± 2.70 kcal/mol, providing a molecular basis for the observed biological effects.
Discussion
Tangeretin acts as an exercise mimetic by upregulating the SESN2/AMPK/PGC-1α pathway, boosting irisin production even without physical activity. By rescuing the suppressed FNDC5 pathway in obese mice, TAN breaks the cycle of metabolic dysfunction. While these results are promising, human clinical trials are necessary to confirm safety and efficacy in humans. Additionally, genetic knockout studies would definitively prove if SESN2 is the exclusive mediator of TAN's metabolic benefits.
Summary updated